Can a rheumatoid arthritis drug save COVID-19 patients from lung failure?
NCT ID NCT04363853
First seen Apr 09, 2026 · Last updated Jun 18, 2026 · Updated 11 times
Summary
This study tests whether the drug tocilizumab can help people with severe or critical COVID-19 who have serious lung problems (ARDS). About 200 adults will receive one or two doses and be followed for 30 days. The goal is to see if the drug improves survival and recovery. There is no placebo group because of the high risk of death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute of Mexico
Mexico City, Mexico City, 14080, Mexico
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.